(Total Views: 659)
Posted On: 05/12/2025 12:34:36 AM
Post# of 154912
IMO the pooled safety data to me means there is potential that;
indications starting out in clinical trials may be able to skip phase 1, or move along much faster.
for other indications with some form of clinical trial having been completed, if they show a signal that patients improve in some way better than standard of care, the next step is phase 3.
I'm unsure if this pooled safety data may open the possibility for trials to use leronlimab as an early line of treatment, rather than start with salvage patients. I think this possibility may come to be sooner than I had earlier expected if the oncology MOA is stunning.
indications starting out in clinical trials may be able to skip phase 1, or move along much faster.
for other indications with some form of clinical trial having been completed, if they show a signal that patients improve in some way better than standard of care, the next step is phase 3.
I'm unsure if this pooled safety data may open the possibility for trials to use leronlimab as an early line of treatment, rather than start with salvage patients. I think this possibility may come to be sooner than I had earlier expected if the oncology MOA is stunning.
(7)
(0)
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
